share_log

Those Who Invested in Prestige Consumer Healthcare (NYSE:PBH) Five Years Ago Are up 144%

Those Who Invested in Prestige Consumer Healthcare (NYSE:PBH) Five Years Ago Are up 144%

五年前投資Prestige Consumer Healthcare(紐約證券交易所代碼:PBH)的人上漲了144%
Simply Wall St ·  03/26 09:44

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. For example, the Prestige Consumer Healthcare Inc. (NYSE:PBH) share price has soared 144% in the last half decade. Most would be very happy with that. Also pleasing for shareholders was the 16% gain in the last three months. But this move may well have been assisted by the reasonably buoyant market (up 8.3% in 90 days).

任何股票(假設你不使用槓桿)的最大損失是你的資金的100%。但好的一面是,如果你以合適的價格購買一家高質量公司的股票,你可以獲得超過100%的收益。例如,Prestige Consumer Healthcare Inc.(紐約證券交易所代碼:PBH)的股價在過去五年中飆升了144%。大多數人會對此感到非常滿意。同樣令股東高興的是過去三個月的16%的漲幅。但是,這一舉措很可能得到了相當活躍的市場(90天內上漲8.3%)的推動。

Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.

讓我們來看看長期的基本面,看看它們是否與股東的回報一致。

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

引用巴菲特的話說:“船隻將在世界各地航行,但Flat Earth Society將蓬勃發展。市場上的價格和價值之間將繼續存在巨大差異...”通過比較每股收益(EPS)和一段時間內的股價變化,我們可以了解投資者對公司的態度是如何隨着時間的推移而變化的。

Prestige Consumer Healthcare's earnings per share are down 1.6% per year, despite strong share price performance over five years. This was, in part, due to extraordinary items impacting earning in the last twelve months.

儘管五年來股價表現強勁,但Prestige Consumer Healthcare的每股收益每年下降1.6%。這在一定程度上是由於非同尋常的項目影響了過去十二個月的收入。

So it's hard to argue that the earnings per share are the best metric to judge the company, as it may not be optimized for profits at this point. Therefore, it's worth taking a look at other metrics to try to understand the share price movements.

因此,很難說每股收益是評判公司的最佳指標,因爲目前每股收益可能還沒有針對利潤進行優化。因此,值得一看其他指標,以了解股價走勢。

On the other hand, Prestige Consumer Healthcare's revenue is growing nicely, at a compound rate of 4.2% over the last five years. It's quite possible that management are prioritizing revenue growth over EPS growth at the moment.

另一方面,Prestige Consumer Healthcare的收入增長良好,在過去五年中複合增長率爲4.2%。目前,管理層很有可能將收入增長置於每股收益增長之上。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下圖中看到收入和收入隨時間推移而發生的變化(點擊圖表查看確切值)。

earnings-and-revenue-growth
NYSE:PBH Earnings and Revenue Growth March 26th 2024
紐約證券交易所:PBH 收益和收入增長 2024 年 3 月 26 日

Take a more thorough look at Prestige Consumer Healthcare's financial health with this free report on its balance sheet.

通過這份免費的資產負債表報告,更全面地了解Prestige Consumer Healthcare的財務狀況。

A Different Perspective

不同的視角

Prestige Consumer Healthcare shareholders are up 15% for the year. But that was short of the market average. It's probably a good sign that the company has an even better long term track record, having provided shareholders with an annual TSR of 20% over five years. It may well be that this is a business worth popping on the watching, given the continuing positive reception, over time, from the market. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 2 warning signs we've spotted with Prestige Consumer Healthcare .

Prestige 消費者醫療保健股東今年上漲了15%。但這低於市場平均水平。這可能是一個好兆頭,表明該公司的長期業績記錄甚至更好,在五年內爲股東提供了20%的年股東總回報率。鑑於隨着時間的推移,市場持續給予積極的歡迎,這很可能是一項值得關注的業務。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。爲此,你應該注意我們在Prestige Consumer Healthcare發現的兩個警告信號。

Of course Prestige Consumer Healthcare may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,Prestige Consumer Healthcare可能不是最好的買入股票。因此,您可能希望看到這批免費的成長股。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論